<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469089</url>
  </required_header>
  <id_info>
    <org_study_id>REVISE28347</org_study_id>
    <secondary_id>2017-004455-22</secondary_id>
    <nct_id>NCT03469089</nct_id>
  </id_info>
  <brief_title>Touchscreen-based Cognitive Tests in Healthy Volunteers</brief_title>
  <official_title>Touchscreen-based Cognitive Tests in Assessment of Ketamine-induced Cognitive Deficits in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib study aims to evaluate applicability of touchscreen-based cognitive test
      battery for assessment of ketamine-induced schizophrenia-like cognitive deficits in healthy
      volunteers. Additionally, the study aims to assess whether ketamine-induced cognitive
      deficits are reversed by modafinil using touchscreen-based test battery for testing of
      cognition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers are measured by
      using touchscreen-based cognitive tests. In addition, the study aims to assess whether
      ketamine-induced cognitive deficits detected by touchscreen-based cognitive tests are
      reversed by modafinil.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects will get each treatment according to balanced latin square design for four treatments with 12 days intervals</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ketamine-induced cognitive deficits</measure>
    <time_frame>15-60 min after initiation of ketamine or placebo infusion</time_frame>
    <description>Ketamine-induced cognitive deficits are measured by using the touchscreen cognitive test battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of modafinil on ketamine-induced cognitive deficits</measure>
    <time_frame>15-60 min after initiation of ketamine or placebo infusion</time_frame>
    <description>The effect of modafinil on ketamine-induced cognitive deficits are measured by using the touchscreen cognitive test battery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ketamine plasma levels</measure>
    <time_frame>14 and 60 min after initiation of ketamine or placebo infusion</time_frame>
    <description>Assessment of ketamine plasma levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain-derived neurotrophic factor serum levels</measure>
    <time_frame>14 and 60 min after initiation of ketamine of placebo infusion</time_frame>
    <description>Assessment of Brain-derived neurotrophic factor serum levels</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cognitive Symptom</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.58/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.58/modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.31/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.58</intervention_name>
    <description>Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)</description>
    <arm_group_label>Ketamine 0.58/placebo</arm_group_label>
    <arm_group_label>Ketamine 0.58/modafinil</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.31</intervention_name>
    <description>Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)</description>
    <arm_group_label>Ketamine 0.31/placebo</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>Modafinil tablet 100 mg placed in a capsule</description>
    <arm_group_label>Ketamine 0.58/modafinil</arm_group_label>
    <other_name>Modafinil Orion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ketamine</intervention_name>
    <description>0.9 % NaCl infusion solution</description>
    <arm_group_label>Placebo/placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for modafinil</intervention_name>
    <description>Placebo capsule for modafinil capsule</description>
    <arm_group_label>Placebo/placebo</arm_group_label>
    <arm_group_label>Ketamine 0.58/placebo</arm_group_label>
    <arm_group_label>Ketamine 0.31/placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian men aged 20-40 years

          -  Body weight 50-100 kg

          -  Body mass index 19-26 kg/cm2

          -  Normal physical examination including heart rate (HR; 50-90/min) blood pressure (BP;
             diastolic 65-90 and systolic 110-140) normal haematological and clinical chemistry
             variables normal ECG as judged by the investigator

        Exclusion Criteria:

          -  Visual disability or red-green color blindness

          -  History of mental health disorders as determined by self-reported a)
             physician-determined diagnoses of mental health disorders, except for nicotine and
             caffeine dependence, or history of suicide attempt; b) medications for mental health
             disorders

          -  History of clinically significant hematological, renal, endocrine, pulmonary,
             gastrointestinal, cardiovascular, hepatic, or neurological disorder

          -  History of orthostatic syncope

          -  History of head injury with sequelae

          -  First-degree relative with a history of psychosis or epilepsy/seizure disorder or of a
             condition with risk of seizures

          -  Current regular medication

          -  Vaccination 2 weeks prior to study or during the study

          -  Known or suspected allergy/hypersensitivity to any drug

          -  History of regular alcohol consumption

          -  Current substance dependence (excluding nicotine and caffeine).

          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
             cigarettes per day

          -  Use of any medication or alcohol 24 hours before each study visit

          -  Education less than high school

          -  Clinically relevant symptoms of depression, anxiety or sleep disturbances

          -  Donation of blood within 1 month prior to study

          -  Participation in any study with an investigational product within 2 months prior to
             study

          -  Clinical signs of suicidal or violent behaviour or psychotic symptoms
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus M Forsberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland, Clinical Research Centre, Brain Research Unit</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>cognitive symptom</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>cognitive testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

